About Q32 Bio Inc.
https://www.q32bio.comQ32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States.
CEO
Jodie Pope Morrison
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-03-26 | Reverse | 1:18 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
ORBIMED ADVISORS LLC
Shares:2.25M
Value:$8.11M
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC
Shares:2.09M
Value:$7.53M
CARLYLE GROUP INC.
Shares:1.1M
Value:$3.97M
Summary
Showing Top 3 of 57
About Q32 Bio Inc.
https://www.q32bio.comQ32 Bio Inc., a clinical-stage biotechnology company, develops biologic therapeutics to restore healthy immune balance in patients with autoimmune and inflammatory diseases driven by pathological immune dysfunction in the United States.
Income Statement
| Period | Revenue | Operating Expense | Net Income | Net Profit Margin | Earnings Per Share | EBITDA |
|---|---|---|---|---|---|---|
| Q3-2025 | $0 | $7.58M ▼ | $-7.39M ▲ | 0% | $-0.6 ▲ | $-7.09M ▲ |
| Q2-2025 | $0 | $9.08M ▼ | $-9.49M ▲ | 0% | $-0.78 ▲ | $-9.1M ▲ |
| Q1-2025 | $0 | $12.23M ▼ | $-11.03M ▲ | 0% | $-0.9 ▲ | $-10.61M ▼ |
| Q4-2024 | $0 | $14.53M ▼ | $-14.19M ▲ | 0% | $-2.33 ▼ | $6.71M ▲ |
| Q3-2024 | $0 | $18.81M | $-17.59M | 0% | $-1.46 | $-18.69M |
Balance Statement
| Period | Cash & Short-term | Total Assets | Total Liabilities | Total Equity |
|---|---|---|---|---|
| Q3-2025 | $49.04M ▼ | $57.78M ▼ | $76.23M ▼ | $-18.45M ▼ |
| Q2-2025 | $54.83M ▼ | $66.12M ▼ | $78.35M ▼ | $-12.23M ▼ |
| Q1-2025 | $65.48M ▼ | $79.07M ▼ | $83.08M ▼ | $-4.01M ▼ |
| Q4-2024 | $77.97M ▼ | $92.33M ▼ | $86.66M ▲ | $5.67M ▼ |
| Q3-2024 | $89.08M | $104.54M | $86.25M | $18.3M |
Cash Flow Statement
| Period | Net Income | Cash From Operations | Cash From Investing | Cash From Financing | Net Change | Free Cash Flow |
|---|---|---|---|---|---|---|
| Q3-2025 | $-7.39M ▲ | $-4.23M ▲ | $0 | $-1.56M ▼ | $-5.79M ▲ | $-4.23M ▲ |
| Q2-2025 | $-9.49M ▲ | $-10.65M ▲ | $0 | $0 | $-10.65M ▲ | $-10.65M ▲ |
| Q1-2025 | $-11.03M ▲ | $-12.48M ▼ | $0 ▲ | $0 ▼ | $-12.48M ▼ | $-12.48M ▼ |
| Q4-2024 | $-14.19M ▲ | $-11.43M ▲ | $-2K ▼ | $317K ▼ | $-11.11M ▼ | $-11.43M ▲ |
| Q3-2024 | $-17.59M | $-19.52M | $9.94M | $997K | $-8.58M | $-19.58M |
CEO
Jodie Pope Morrison
Compensation Summary
(Year )
Split Record
| Date | Type | Ratio |
|---|---|---|
| 2024-03-26 | Reverse | 1:18 |
ETFs Holding This Stock
Summary
Showing Top 1 of 11
Ratings Snapshot
Rating : C+
Most Recent Analyst Grades
Grade Summary
Showing Top 3 of 3
Price Target
Institutional Ownership
ORBIMED ADVISORS LLC
Shares:2.25M
Value:$8.11M
ATLAS VENTURE LIFE SCIENCE ADVISORS, LLC
Shares:2.09M
Value:$7.53M
CARLYLE GROUP INC.
Shares:1.1M
Value:$3.97M
Summary
Showing Top 3 of 57